PLB 1001

Drug Profile

PLB 1001

Alternative Names: Bozitinib; PLB-1001

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator Beijing Pearl Biotechnology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glioma; Non-small cell lung cancer

Most Recent Events

  • 01 Sep 2016 Phase-I clinical trials in Glioma (Recurrent, Second-line therapy or greater) in China (PO) (NCT02978261)
  • 01 Apr 2016 Phase-I clinical trials in Non-small cell lung cancer in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top